Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

NCT03559387 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Study redesign

Conditions

Chemotherapy-induced Neutropenia

Interventions

DRUG: ANF-RHO™
DRUG: Neulasta®

Sponsor

Prolong Pharmaceuticals